YiChang HEC ChangJiang Pharmaceutical Co., Ltd. provided group earnings guidance for the year ended 31 December 2020. Based on the unaudited consolidated management accounts currently available to the Group and the preliminary assessment by the company's management, it is expected that the Group will record a revenue of approximately RMB 2,345 million for the year ended 31 December 2020, representing a decrease of approximately 62% as compared to the year ended 31 December 2019. The expected decrease in revenue of the Company is primarily attributable to the COVID-19 pandemic, causing a significant drop in visits to medical institutions, such as hospitals of different tiers, resulting in a decline in sales volume of Kewei, the Group's core product. With the pandemic in China being under control, outpatient visits are on the rise and gradual recovery in the sales volume of the Group's core product is expected.